Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism
- PMID: 33314804
- PMCID: PMC7801161
- DOI: 10.4111/icu.20200194
Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism
Abstract
Purpose: Does surgical approach (minimally invasive vs. open) and type (radical vs. partial nephrectomy) affects opioid use and workplace absenteeism.
Materials and methods: Retrospective multivariable regression analysis of 2,646 opioid-naïve patients between 18 and 64 undergoing radical or partial nephrectomy via either a minimally invasive vs. open approach for kidney cancer in the United States between 2012 and 2017 drawn from the IBM Watson Health Database was performed. Outcomes included: (1) opioid use in opioid-naïve patients as measured by opioid prescriptions in the post-operative setting at early, intermediate and prolonged time periods and (2) workplace absenteeism after surgery.
Results: Patients undergoing minimally invasive surgery had a lower odds of opioid use in the early and intermediate post-operative periods (early: odds ratio [OR], 0.77; 95% confidence interval [CI], 0.62-0.97; p=0.02, intermediate: OR, 0.60; 95% CI, 0.48-0.75; p<0.01), but not in the prolonged setting (prolonged: OR, 1.00; 95% CI, 0.75-1.34; p=0.98) and had earlier return to work (minimally invasive vs. open: -10.53 days; 95% CI, -17.79 to -3.26; p<0.01). Controlling for approach, patient undergoing partial nephrectomy had lower rates of opioid use across all time periods examined and returned to work earlier than patients undergoing radical nephrectomy (partial vs. radical: -14.41 days; 95% CI, -21.22 to -7.60; p<0.01).
Conclusions: Patients undergoing various forms of surgery for kidney cancer had lower rates of peri-operative opioid use, fewer days of workplace absenteeism, but no difference in long-term rates of opioid use in patients undergoing minimally invasive as compared to open surgery.
Keywords: Absenteeism; Kidney neoplasm; Minimally invasive surgical procedures; Nephrectomy; Opioids.
© The Korean Urological Association, 2021.
Conflict of interest statement
Quoc-Dien Trinh reports personal fees from Astellas, Bayer, Janssen, Insightec and Intuitive Surgical. Adam S. Kibel reports consulting fees from Janssen, Merck, Bristol-Myers Squibb, Advantage, Insightec, and Profound. Richard D. Urman reports research funding from Merck and Medtronic and consulting fees from 3M, Mallinckrodt and Sandoz. Prokar Dasgupta is funded by the MRC Centre for Transplantation, NIHR Biomedical Research Centre, Kings College London, The Prostate Cancer Research Centre, The Vattikuti Foundation and The Urology Foundation.
Figures
References
-
- Cheung H, Wang Y, Chang SL, Khandwala Y, Del Giudice F, Chung BI. Adoption of robot-assisted partial nephrectomies: a population-based analysis of U.S. surgeons from 2004 to 2013. J Endourol. 2017;31:886–892. - PubMed
-
- Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol. 2012;61:679–685. - PubMed
-
- Garisto J, Bertolo R, Dagenais J, Sagalovich D, Fareed K, Fergany A, et al. Robotic versus open partial nephrectomy for highly complex renal masses: comparison of perioperative, functional, and oncological outcomes. Urol Oncol. 2018;36:471.e1–471.e9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
